| abstract |
The invention concerns any lipopeptide characterised in that it comprises: a peptide part comprising the peptide sequence consisting of about 30 to about 50 of the last contiguous amino acids of the interferon-η (IFN-η) C-terminal end of mammals, whereof, if required, the last 3 to 20 amino acids have been suppressed; and one or several lipophilic parts comprising a C4-C20 chain of carbon atoms, saturated or unsaturated, linear or branched, or a steroid group. The invention also concerns any lipopeptide such as defined above containing one or several CD8, and/or CD4, and/or B epitopes. The invention further concerns medicines or vaccines containing any polypeptide such as defined above. |